<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        272-212-11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOX 250MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        35.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; Pharmacotherapeutic group:&nbsp;<br />Levox tablets contain a medicine called levofloxacin, used in adults 18 years or older. This&nbsp;<br />belongs to a group of medicines called antibiotics. Levofloxacin is a &lsquo;quinolone&rsquo; antibiotic. It&nbsp;<br />works by killing the bacteria that cause infections in your body.&nbsp;<br />&nbsp;<br />&minus; Therapeutic indications:&nbsp;<br />Levox tablets can be used to treat infections of the:&nbsp;<br />&bull; Nasal sinuses.&nbsp;<br />&bull; Lungs, in people with long-term breathing problems or pneumonia.&nbsp;<br />&bull; Urinary tract, including your kidneys or bladder.&nbsp;<br />&bull; Prostate gland, where you have a long lasting infection. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br />&bull; Skin and underneath the skin, including muscles. This is sometimes called &lsquo;soft tissue&rsquo;.&nbsp;<br />Sometimes infections are caused by viruses rather than by bacteria. Examples include viral&nbsp;<br />infections in the sinuses and lungs, such as the common cold or flu. Antibiotics, including&nbsp;<br />Levox, do not kill viruses.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not take this medicine and tell your doctor if:&nbsp;<br />&bull; You are allergic to levofloxacin, any other quinolone antibiotic such as moxifloxacin,&nbsp;<br />ciprofloxacin or ofloxacin or any of the other ingredients of Levox tablets (listed in Section 6&nbsp;<br />below). Signs of an allergic reaction include rash, swallowing or breathing problems, and&nbsp;<br />swelling of your lips, face, throat or tongue.&nbsp;<br />&bull; You have ever had epilepsy.&nbsp;<br />&bull; You have ever had a problem with your tendons such as tendonitis that was related to&nbsp;<br />treatment with a &lsquo;quinolone antibiotic&rsquo;. &nbsp;</p><p>&bull; You are a child or a growing teenager.&nbsp;<br />&bull; You are pregnant, might become pregnant or think you may be pregnant.&nbsp;<br />&bull; You are breast-feeding.&nbsp;<br />Do not take this medicine if any of the above applies to you. If you are not sure, talk to your&nbsp;<br />doctor or pharmacist before taking Levox tablets.&nbsp;<br />Due to possible side effects, Levox is not recommended for pediatric and adolescent patients -<br />less than 18- except for the prevention of anthrax for those who are 6 months and older and&nbsp;<br />have breathed the anthrax bacteria germ.&nbsp;<br />Warning:&nbsp;<br />Tendon rupture or swelling of the tendon (tendinitis):&nbsp;<br />- Tendons are the tough cords of tissue that connect muscles to bones. &nbsp;Pain, swelling, tears,&nbsp;<br />and inflammation of tendons including the back of the ankle (Achilles), shoulder, hand, or&nbsp;<br />other tendon sites can happen in people of all ages who take quinolone antibiotics, including&nbsp;<br />Levox. The risk of getting tendon problems is higher if you: &nbsp;<br />&bull; Are over 60 years of age. &nbsp;<br />&bull; Are taking steroids (corticosteroids). &nbsp;<br />&bull; Have had a kidney, heart or lung transplant. &nbsp;<br />&bull; Swelling of the tendon (tendinitis) and tendon rupture (breakage) have also happened in&nbsp;<br />patients who take quinolones who do not have the above risk factors. &nbsp;<br />&bull; Other reasons for tendon ruptures can include: &nbsp;<br />- Physical activity or exercise. &nbsp;<br />- Kidney failure. &nbsp;<br />- Tendon problems in the past, such as in people with rheumatoid arthritis (RA). &nbsp;<br />&bull; Call your doctor right away at the first sign of tendon pain, swelling or inflammation. Stop&nbsp;<br />taking Levox until tendinitis or tendon rupture has been ruled out by your healthcare provider.&nbsp;<br />Avoid exercise and using the affected area. The most common area of pain and swelling is the&nbsp;<br />Achilles tendon at the back of your ankle. This can also happen with other tendons. &nbsp;<br />&bull; Get medical help right away if you get any of the following signs or symptoms of a tendon&nbsp;<br />rupture: &nbsp;<br />- Hear or feel a snap or pop in a tendon area. &nbsp;<br />- Bruising right after an injury in a tendon area.&nbsp;<br />- Unable to move the affected area or bear weight. &nbsp;<br />b. Take special care with Levox.&nbsp;<br />Check with your doctor or pharmacist before taking your medicine if you:&nbsp;<br />&bull; Are 60 years of age or older.&nbsp;<br />&bull; Are using corticosteroids.&nbsp;<br />&bull; Have ever had a fit (seizure).&nbsp;<br />&bull; Have tendon problems. &nbsp;<br />&bull; Have low blood potassium (hypokalemia). &nbsp;<br />&bull; Have had damage to your brain due to a stroke or other brain injury.&nbsp;<br />&bull; Have kidney problems.&nbsp;<br />&bull; Have something known as &lsquo;glucose &ndash; 6 &ndash; phosphate dehydrogenase deficiency&rsquo;. &nbsp;<br />&bull; Have ever had mental health problems.&nbsp;<br />&bull; Have ever had heart problems.&nbsp;</p><p>&bull; Are diabetic.&nbsp;<br />&bull; Have bone and joint problems such as rheumatoid arthritis (RA) or other history of joint&nbsp;<br />problems.&nbsp;<br />&bull; Have nerve problems. &nbsp;<br />&bull; Have or anyone in your family has an irregular heartbeat, especially a condition called &ldquo;QT&nbsp;<br />prolongation&rdquo;. &nbsp;<br />&bull; Have ever had liver problems. &nbsp;<br />If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before&nbsp;<br />taking Levox tablets.&nbsp;<br />c. Using other medicines, herbal or dietary supplements:&nbsp;<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other&nbsp;<br />medicines. Do not start a new medicine without first consulting a doctor or pharmacist.&nbsp;<br />This includes medicines you buy without prescription, including herbal medicines. This is&nbsp;<br />because Levox tablets can affect the way some other medicines work. In addition, some&nbsp;<br />medicines can affect the way Levox tablets work.&nbsp;<br />In particular, tell your doctor if you are taking any of the following medicines. This is because&nbsp;<br />it can increase the chance of you getting side effects, when taken with Levox tablets:&nbsp;<br />&bull; Corticosteroids: used for inflammation. You may be more likely to have inflammation and/or&nbsp;<br />breakage of your tendons.&nbsp;<br />&bull; Warfarin: used to thin the blood. You may be more likely to have a bleed. Your doctor may&nbsp;<br />need to take regular blood tests to check how well your blood can clot.&nbsp;<br />&bull; Theophylline: used for breathing problems. You are more likely to have a fit (seizure) if taken&nbsp;<br />with Levox tablets.&nbsp;<br />&bull; Non-steroidal anti-inflammatory drugs (NSAIDS): used for pain and inflammation such as&nbsp;<br />aspirin, ibuprofen, fenbufen, ketoprofen and indomethacin. You are more likely to have a fit&nbsp;<br />(seizure) if taken with Levox tablets.&nbsp;<br />&bull; Ciclosporin: used after organ transplants. You may be more likely to get the side effects of&nbsp;<br />Ciclosporin.&nbsp;<br />&bull; Medicines known to affect the way your heart beats: This includes medicines used for&nbsp;<br />abnormal heart rhythm (antiarrhythmics such as quinidine and amiodarone).&nbsp;<br />&bull; Tricyclic antidepressants: such as amitriptyline and imipramine. &nbsp;<br />&bull; Macrolide antibiotics: such as erythromycin,azithromycin and Clarithromycin.&nbsp;<br />&bull; Any oral anti-diabetes medicine or insulin.&nbsp;<br />&bull; Anti-psychotic medicines. &nbsp;<br />&bull; A water pill (diuretic). &nbsp;<br />&bull; Probenecid: (used for gout).&nbsp;<br />&bull; Cimetidine: used for ulcers and heartburn. &nbsp;<br />Special care should be taken when taking either of these medicines with Levox. &nbsp;<br />If you have kidney problems, your doctor may want to give you a lower dose.&nbsp;<br />Do not take Levox tablets at the same time as the following medicines. Either 2 hours&nbsp;<br />before or 2 hours after taking these products: &nbsp;<br />&bull; Iron tablets (for anemia), multivitamin, or other product that has magnesium, aluminum, iron&nbsp;<br />or zinc. &nbsp;<br />&bull; Magnesium or aluminum-containing antacids (for acid or heartburn). &nbsp;</p><p>&bull; Sulcralfate (for stomach ulcers). &nbsp;<br />&bull; Didanosine antiviral drug for HIV.&nbsp;<br />This is because it can affect the way Levox tablets work.&nbsp;<br />Urine tests for opiates:&nbsp;<br />Urine tests may show &ldquo;false-positive&rdquo; results for strong painkillers called &ldquo;opiates&rdquo; in people&nbsp;<br />taking Levox ( levofloxacin) tablets. If your doctor is due to take a urine test, tell him you are&nbsp;<br />taking Levox tablets.&nbsp;<br />d. Pregnancy and breast-feeding:&nbsp;<br />Do not take this medicine if:&nbsp;<br />&bull; You are pregnant, might become pregnant or think you may be pregnant.&nbsp;<br />&bull; You are breast-feeding or planning to breast-feed. &nbsp;<br />Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant or&nbsp;<br />breast-feeding.&nbsp;<br />e. Driving and using machines:&nbsp;<br />You may get side effects after taking this medicine, including feeling dizzy, sleepy, a spinning&nbsp;<br />feeling (vertigo) or changes to your eyesight. Some of these side effects can affect you being&nbsp;<br />able to concentrate and your reaction speed. If this happens, do not drive or carry out any work&nbsp;<br />that requires a high level of attention.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Levox tablets exactly as your doctor has told you. &nbsp;<br />&bull; Take this medicine by mouth.&nbsp;<br />&bull; Swallow the tablets whole with a drink of water.&nbsp;<br />&bull; The tablets may be taken during meals or at any time between meals.&nbsp;<br />&bull; Your doctor will decide on how many Levox tablets you should take.&nbsp;<br />&bull; The dose will depend on the type of infection you have and where the infection is in your&nbsp;<br />body.&nbsp;<br />&bull; The length of your treatment will depend on how serious your infection is.&nbsp;<br />Adults and the elderly with normal renal function:&nbsp;<br />Acute Bacterial Sinuses:&nbsp;<br />&bull; 500 mg , once each day for 10-14 days.&nbsp;<br />&bull; 750 mg , once each day for 5 days.&nbsp;<br />Pneumonia:&nbsp;<br />Nosocomial Pneumonia:&nbsp;<br />&bull; 750 mg, once each day for 7-14 days.&nbsp;<br />Community Acquired Pneumonia:&nbsp;<br />&bull; 500 mg , once each day for 10-14 days. &nbsp;<br />&bull; 750 mg , once each day for 5 days.&nbsp;<br />Acute bacterial exacerbation of chronic bronchitis:&nbsp;<br />&bull; 500 mg , once each day for 7 days.&nbsp;<br />Complicated urinary tract infection or acute pyelonephritis:&nbsp;<br />&bull; 750 mg, each day for 5 days.&nbsp;<br />&bull; 250 mg, each day for 10 days.&nbsp;<br />Uncomplicated urinary tract infection:&nbsp;<br />&bull; 250 mg, each day for 3 days.&nbsp;</p><p>Chronic bacterial Prostatitis:&nbsp;<br />&bull; 500 mg, once each day for 28 days.&nbsp;<br />Complicated skin and skin structure infections (SSSI):&nbsp;<br />&bull; 750 mg, once each day for 7-14 days.&nbsp;<br />Uncomplicated (SSSI):&nbsp;<br />&bull; 500 mg, once each day for 7-10 days. &nbsp;<br />Adults with kidney problems:&nbsp;<br />Your doctor may need to give you a lower dose.&nbsp;<br />Children and Teenagers:&nbsp;<br />This medicine must not be given to children or teenagers below 18 years.&nbsp;<br />Children have a higher chance of getting bone, joint, or tendon problems such as pain or&nbsp;<br />swelling while taking levofloxacin.&nbsp;<br />If you have been prescribed Levox after being exposed to anthrax:&nbsp;<br />The Dose:&nbsp;<br />&bull; 500 mg, once each day for 60 days for adults and for children 6 months and older and their&nbsp;<br />weight is more than 50 kg.&nbsp;<br />Levox has been approved to lessen the chance of getting anthrax disease or worsening of the&nbsp;<br />disease after you are exposed to the anthrax bacteria germ. &nbsp;<br />Take Levox exactly as prescribed by your healthcare provider. Do not stop taking Levox&nbsp;<br />without talking with your healthcare provider. If you stop taking Levox too soon, it may not&nbsp;<br />prevent you from getting the anthrax disease. &nbsp;<br />It is not known if it is safe to use Levox for more than 28 days in adults and for more than 14&nbsp;<br />days in children 6 months of age and older. &nbsp;<br />If you are pregnant, or plan to become pregnant while taking Levox, you and your healthcare&nbsp;<br />provider should decide whether the benefits of taking Levox for anthrax are more important&nbsp;<br />than the risks. &nbsp;<br />In children 6 months and older who have breathed the anthrax bacteria germ: &nbsp;<br />&bull; Levox is used to prevent anthrax disease (inhalation anthrax). &nbsp;<br />&bull; It is not known if Levox is safe and works in children under the age of 6 months. &nbsp;<br />A. If you take more Levox tablets than you should:&nbsp;<br />If you accidentally take more tablets than you should, tell a doctor or get other medical advice&nbsp;<br />straight away. Take the medicine pack with you. This is so the doctor knows what you have&nbsp;<br />taken. The following effects may happen:&nbsp;<br />Convulsive fits (seizures), feeling confused, dizzy, less conscious and heart problems leading&nbsp;<br />to uneven heart beats as well as feeling sick (nausea).&nbsp;<br />B. If you forget to take Levox tablets:&nbsp;<br />If you forgot to take a dose, take it as soon as you remember unless it is nearly time for your&nbsp;<br />next dose. Do not double-up the next dose to make up for the missed dose.&nbsp;<br />C. If you stop taking Levox tablets:&nbsp;<br />Do not stop taking Levox tablets just because you feel better. It is important that you complete&nbsp;<br />the course of tablets that your doctor has prescribed for you. If you stop taking the tablets too&nbsp;<br />soon, the infection may return, your condition may get worse or the bacteria may become&nbsp;<br />resistant to the medicine.&nbsp;<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Levox can cause side effects, although not everybody gets them. These&nbsp;<br />effects are normally mild or moderate and often disappear after a short time.&nbsp;<br />Stop taking Levox tablets and see a doctor straight away if you notice the following side effect:&nbsp;<br />Very rare (affects less than 1 person in 10,000):&nbsp;<br />&bull; You have an allergic reaction. Even after only one dose. The signs may include a rash,&nbsp;<br />swallowing or breathing problems, hives, hoarseness, rapid heart beat, faint, and swelling of&nbsp;<br />your lips, face, throat, or tongue.&nbsp;<br />&bull; Burning, tingling, pain, weakness and numbness in your arms, hands, legs or feet. These may&nbsp;<br />be signs of something called &lsquo;peripheral neuropathy&rsquo;. &nbsp;See a doctor straight away if you notice&nbsp;<br />any of these side effects. &nbsp;<br />Rare (affects less than 1 person in 1000):&nbsp;<br />&bull; Intestine infection (Pseudomembranous colitis): &nbsp;<br />Watery diarrhea, diarrhea that does not go away or which may have blood in it, possibly with&nbsp;<br />stomach cramps and a high temperature. These could be signs of a severe bowel problem.&nbsp;<br />&bull; Pain and inflammation in your tendons. The Achilles tendon is affected most often and in&nbsp;<br />some cases, the tendon could break.&nbsp;<br />&bull; Fits (convulsions).&nbsp;<br />Other:&nbsp;<br />&bull; Severe skin rashes that may include blistering or peeling of the skin around your lips, eyes,&nbsp;<br />mouth, nose and genitals.&nbsp;<br />&bull; Loss of appetite, skin and eyes becoming yellow in colour, dark-coloured urine, itching, or&nbsp;<br />tender stomach (abdomen). These may be signs of liver problems.&nbsp;<br />Tell your doctor if any of the following side effects gets serious or lasts longer than a few&nbsp;<br />days:&nbsp;<br />Common (affects less than 1 person in 10):&nbsp;<br />&bull; Feeling sick (nausea) and diarrhea.&nbsp;<br />&bull; Increase in the level of some liver enzymes in your blood.&nbsp;<br />&bull; Headache, feeling dizzy.&nbsp;<br />&bull; Insomnia.&nbsp;<br />Uncommon (affects less than 1 person in 100):&nbsp;<br />&bull; Itching and skin rash.&nbsp;<br />&bull; Loss of appetite, stomach upset or indigestion (dyspepsia), being sick (vomiting) or pain in&nbsp;<br />your stomach area, feeling bloated (flatulence) or constipation.&nbsp;<br />&bull; A spinning feeling (vertigo), feeling sleepy, sleeping problems or feeling nervous.&nbsp;<br />&bull; General weakness.&nbsp;<br />Rare (affects less than 1 person in 1,000):&nbsp;<br />&bull; Tingly feeling in your hands and feet (paraesthesia) or trembling.&nbsp;<br />&bull; Feeling stressed (anxiety), depressed, mental problems, feeling restless (agitation) or feeling&nbsp;<br />confused.&nbsp;<br />&bull; Unusual fast beating of your heart or low blood pressure.&nbsp;<br />&bull; Joint pain or muscle pain.&nbsp;<br />&bull; Bruising and bleeding easily due to a lowering in the number of blood platelets.&nbsp;<br />&bull; Low number of white blood cells (called neutropenia).&nbsp;</p><p>&bull; Difficulty breathing or wheezing (bronchospasm).&nbsp;<br />&bull; Severe itching or hives (called urticaria).&nbsp;<br />Very rare (affects less than 1 person in 10,000):&nbsp;<br />&bull; Increased sensitivity of your skin to sun and ultraviolet light.&nbsp;<br />&bull; Low blood sugar levels (hypoglycemia) and high blood sugar (hyperglycemia). This is&nbsp;<br />important for people that have diabetes.&nbsp;<br />&bull; Problems with your hearing or eyesight or changes in the way things taste and smell.&nbsp;<br />&bull; Seeing or hearing things that are not there (hallucinations), change in your opinion and&nbsp;<br />thoughts (psychotic reactions) with a chance of having suicidal thoughts.&nbsp;<br />&bull; Loss of circulation (anaphylactic like shock).&nbsp;<br />&bull; Muscle weakness. This is important in people with myasthenia gravis (a rare disease of the&nbsp;<br />nervous system). &nbsp;<br />&bull; Inflammation of the liver, changes in the way your kidney works and occasional kidney&nbsp;<br />failure which may be due to an allergic kidney reaction called interstitial nephritis.&nbsp;<br />&bull; Fever, sore throat and a general feeling of being unwell that does not go away. This may be&nbsp;<br />due to a lowering in the number of white blood cells.&nbsp;<br />&bull; Fever and allergic lung reactions.&nbsp;<br />Other side effects include:&nbsp;<br />&bull; Lowering in red blood cells (anemia). This can make the skin pale or yellow due to damage&nbsp;<br />of the red blood cells and lowering in the number of all types of blood cells.&nbsp;<br />&bull; Exaggerated immune response (hypersensitivity).&nbsp;<br />&bull; Sweating too much (hyperhidrosis).&nbsp;<br />&bull; Pain, including pain in the back, chest and extremities.&nbsp;<br />&bull; Problems moving and walking.&nbsp;<br />&bull; Attacks of porphyria in people who already have porphyria.&nbsp;<br />&bull; Inflammation of your tubes that carry blood around your body (vessels) due to an allergic&nbsp;<br />reaction.&nbsp;<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,&nbsp;<br />please tell your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; Keep out of the reach and sight of children.&nbsp;<br />&minus; Store below 30&deg;C, Store in the original carton.&nbsp;<br />&minus; Do not use Levox after the expiry date which is stated on the carton.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is levofloxacin. Each tablet of Levox 250 mg tablets contains 250 mg of&nbsp;<br />levofloxacin, each tablet of Levox 500 mg tablets contains 500 mg of levofloxacin and each&nbsp;<br />tablet of Levox 750 mg tablets contains 750 mg of levofloxacin.&nbsp;<br />Excipients for core: Hydroxypropyl methylcellulose EP, crospovidone NF, silicified&nbsp;<br />microcrystalline cellulose, and magnesium stearate.&nbsp;<br />Excipients for film coating: Polysorbate 80 EP, titanium dioxide EP, purified talc EP,&nbsp;<br />polyethylene glycol MW 6000 EP, hydroxypropyl methylcellulose EP, iron oxide yellow.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Levox tablets are film-coated tablets for oral use. The tablets are oblong with light yellow 
colour. 
Levox 250, 500, and 750 mg are available in pack sizes of 5 tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by SPIMACO&nbsp;<br />AlQassim pharmaceutical plant,&nbsp;<br />Saudi Pharmaceutical Industries &amp;&nbsp;<br />Medical Appliance Corporation,&nbsp;<br />Saudi Arabia.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2011. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>المجموعة العلاجية الدوائية التي ينتمي إليها:</strong></p><p>تحتوي أقراص ليفوكس على دواء يسمى ليفوفلوكساسين والذي يستخدم في علاج المرضى من عمر 18 عاما فأكثر. و تنتمي مادة ليفوفلوكساسين لإحدى مجموعات&nbsp; المضادات الحيوية والتي تسمى الكوينولونات. وتعمل مادة ليفوفلوكساسين على قتل البكتيريا التي تسبب الأمراض المعدية في جسمك.</p><p><strong>الدواعي العلاجية:</strong></p><p>تسخدم أقراص ليفوكس في علاج الأمراض المعدية التي تصيب:</p><ul><li><strong>&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>الجيوب الأنفية.</li><li><strong>&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>الرئتين وذلك في الأفراد الذين يعانون من مشاكل تنفسية طويلة الأمد أو الذين يعانون من الالتهاب الرئوي.</li><li><strong>&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>الجهاز البولي ويشمل الكلى والمثانة .</li><li><strong>&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>غدة البروستاتا وذلك في حالة حدوث العدوى طويلة الأمد.</li><li><strong>&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>الجلد والأنسجة تحت الجلد والتي تشمل العضلات. وتسمى أيضا&nbsp; الأنسجة تحت الجلد بالأنسجة الرخوة.</li></ul><p>&nbsp;في بعض الأحيان تكون الفيروسات سببا&nbsp; للإصابة بالأمراض المعدية،&nbsp; ومثال على ذلك حالات العدوى الفيروسية التي تصيب الجيوب الأنفية والرئتين مثل حالات البرد والأنفلونزا. إن المضادات الحيوية وتشمل ليفوكس، لا تقوم بقتل الفيروسات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ. لاتستعمل هذا الدواء واستشرالطبيب المعالج إذا :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك فرط تحسس لمادة ليفوفلوكساسين أو لأي من المضادات الحيوية من مجموعة الكوينولونات مثل موكسيفلوكساسين، سيبروفلوكساسين أو أوفلوكساسين أو لأي من مكونات أقراص ليفوكس (والمذكورة في الفقرة رفم 6).&nbsp; وتكون علامات فرط التحسس على هيئة طفح جلدي، مشاكل في البلع أو التنفس، و تورم في الشفتين، الوجه، الحلق أو اللسان.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد أصبت سابقا بمرض الصرع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل بأوتار العضلات مثل التهاب الأوتار والمتعلقة باستخدام المضادات الحيوية التي تنتمي لمجموعة الكوينولونات.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان المريض طفلا أو في مرحلة المراهقة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت المريضة حامل أو من من المحتمل&nbsp; أن تكون حاملا.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت المريضة من الأمهات المرضعات.</p><p>لايجب تناول هذا الدواء إذا كانت تنطبق عليك أي من النقاط المذكورة أعلاه. تحدث مع الطبيب المعالج أو الصيدلي قبل تناول أقراص ليفوكس في حالة عدم التأكد إذا ماكانت هذه الشروط تنطبق عليك أم لا.</p><p>نظرا لاحتمالية حدوث التأثيرات الجانبية بشكل كبير في الأطفال والمراهقين أقل من 18 عام، لايعطى ليفوكس لهذه الفئة من المرضى إلا في حالة الوقاية من مرض الجمرة الخبيثة وذلك في المرضى الذين يكون عمرهم 6 أشهر أو أكثر وتعرضوا لاستنشاق جرثومة الجمرة الخبيثة.</p><p><strong>تحذير</strong></p><p><strong>تمزق الأوتار أو تورم الوتر ( التهاب الأوتار):</strong></p><p>- الأوتار هي تلك الأحبال التي تربط العضلات بالعظام. قد تحدث آلام، تورم ، تمزق و التهابات في الأوتار وتتضمن خلف الكاحل (وتر أخيليس)، الكتف، اليدين، والأماكن الأخرى التي تحتوي على أوتار وذلك في جميع الأعمار عند المرضى الذين يتناولون المضادات الحيوية من مجموعة الكوينولونات و تشمل ليفوكس. وتزداد خطورة حدوث هذه المشاكل في الأوتار إذا كان:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عمر المريض أكثر من 60 عاما.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المريض يتناول أدوية من مجموعة الستيرويدات.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المريض قد قام بعملية نقل كلية، قلب، أو رئة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد حدث للمريض تورم في الوتر(التهاب الوتر) وتمزق في الوتر عند تناوله أحد المضادات الحيوية من مجموعة الكوينولونات وكان المريض لايعاني من أي من عوامل الخطورة السابق ذكرها.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أسباب أخرى قد تؤدي إلى تمزق الوتر وتشمل:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيام بالتمارين والنشاط البدني.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل وظائف الكلى.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل سابقة في الوتر مثل تلك التي تحدث في مرضى التهاب المفاصل الروماتويدي.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب الاتصال بالطبيب المعالج في حالة ظهور أول علامات آلام الوتر ، تورم الوتر أو التهاب الوتر. في هذه الحالة، يجب التوقف عن تناول ليفوكس حتى يتأكد الطبيب المعالج من أن هذه العلامات لاتتعلق بالتهاب الوتر أو تمزق الوتر. يجب أيضا تجنب القيام بالتمارين البدنية في المنطقة المتأثرة من الجسم. إن أكثر المناطق المتأثرة بحدوث الآلام والتمزق هي خلف الكاحل ( وتر أخيليس). قد تحدث هذه التأثيرات في أوتار في أماكن أخرى.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب طلب المساعدة الطبية في الحال في حالة حدوث أي من الأعراض أو العلامات التالية والتي قد تتعلق بتمزق الوتر مثل:&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سماع أو الإحساس بصكة أو طقطقة في منطقة الوتر.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث كدمة مباشرة بعد الإصابة في منطقة الوتر.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على القيام بتحريك المنطقة المصابة أو عدم تحمل الأوزان.</p><p>&nbsp;</p><p><strong>ب. الاحتياطات عند تناول ليفوكس:</strong></p><p>يجب التأكد من الطبيب أو الصيدلي قبل تناول هذا الدواء إذا :</p><ul><li>كان عمرك 60 عاما أو أكثر.</li><li>تتناول أدوية من مجموعة الكورتيكوستيرويدات.</li><li>&nbsp;حدث لك من قبل نوبات عصبية .</li><li>كانت لديك مشاكل في الأوتار.</li><li>كان لديك نقص في بوتاسيوم الدم.</li><li>حدث لديك سابقا ضررا بالمخ جراء سكتة دماغية أو أي إصابة أخرى بالمخ.</li><li>كانت لديك مشاكل بالكلى.</li><li>كنت تعاني من نقص في إنزيم نازعة هيدروجين الجلوكوز-6-فسفات.</li><li>حدث لك من قبل مشاكل نفسية مرضية.</li><li>حدث لك من قبل مشاكل صحية بالقلب . &nbsp;</li><li>كنت مريضا بالسكري.</li><li>كان لديك مشاكل متعلقة بالعظام والمفاصل متل التهاب المفاصل الروماتويدي أو تاريخ مرضي آخر متعلق بمشاكل في المفاصل.</li><li>كانت لديك مشاكل في الأعصاب.</li><li>كان لديك أو لدى أحد من أفراد عائلتك اضطرابات في دقات القلب وبخاصة حالة تسمى إطالة فترة QT &nbsp;في مخطط كهربية القلب.</li><li>كانت لديك مشاكل في الكبد.</li></ul><p>تحدث مع الطبيب المعالج أو الصيدلي قبل أن تتناول ليفوكس إذا لم تكن متأكدا من أن أي من الحالات السابقة متعلقة بك.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>ج</strong><strong> - </strong><strong>التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات</strong><strong> </strong><strong>غذائية:</strong></p><p>أخبر الطبيب المعالج أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرا أي أدوية أخرى. لا تبدأ بتناول أي علاج آخر جديد قبل أن تستشير الطبيب المعالج أو الصيدلي.</p><p>ويتضمن ذلك الأدوية التي قد يتم شراؤها بدون وصفة طبية و تشمل العلاج بالأعشاب. ويرجع ذلك إلى أن ليفوكس قد يؤثرعلى طريقة عمل بعض الأدوية الأخرى. بالإضافة إلى ذلك قد تقوم بعض الأدوية بالتأثير على طريقة عمل ليفوكس.</p><p><strong>قم بإخبار الطبيب المعالج إذا كنت تتناول أي من الأدوية التالي ذكرها. وذلك نظرا لأن هذه الأدوية قد تزيد من فرصة&nbsp; حدوث الآثار الجانبية لديك إذا تم تناولها مع ليفوكس:</strong></p><ul><li><strong>الكورتيكوستيرويدات:</strong> والتي تستخدم في علاج حالات الالتهاب. قد تزداد احتمالية اصابتك بالتهاب و/أو حدوث تمزق بالأوتار.</li><li><strong>وارفارين:</strong> يستخدم كمضاد لتخثر الدم. قد تزداد القابلية للنزيف لديك. يجب أن يقوم الطبيب المعالج بسحب عينات&nbsp; من الدم&nbsp; بصورة دورية وذلك لمعرفة مدى قدرة الدم على التخثر.</li><li><strong>ثيوفيللين:</strong> يستخدم لمشاكل التنفس. قد تزداد لديك القابلية لحدوث نوبات عصبية&nbsp; عند تناوله مع ليفوكس.</li><li><strong>مضادات الالتهاب غير الستيرويدية:</strong> وتستخدم في حالات الألم والالتهاب مثل الأسبرين، إيبوبروفين، فينبيوفين، كيتوبروفين، و إندوميثاسين. قد تزداد لديك القابلية لحدوث نوبات عصبية عند تناوله مع ليفوكس.</li><li><strong>سيكلوسبورين:</strong> يستخدم بعد عمليات نقل الأعضاء. قد تزداد لديك فرصة حدوث الآثار الجانبية جراء استخدام سيكلوسبورين وذلك عند تناوله مع ليفوكس.</li><li><strong>الأدوية المعروفة بتأثيرها على ضربات قلبك:</strong> وتضمن الأدوية التي تستخدم في علاج خلل نظم القلب.&nbsp; مثل مضادات اضطراب النظم&nbsp; القلبي مثل الكينيدين ، أميودارون.</li><li><strong>مضادات الاكتئاب ثلاثية الحلقة:</strong> مثل أميتريبتيلين و إيميبرامين.</li><li><strong>المضادات الحيوية من مجموعة الماكروليد:</strong> مثل إيريثرومايسين، أزيثرومايسين ، و كلارثرومايسين.</li><li>&nbsp;<strong>مضادات السكري التي يتم تناولها عن طريق الفم أو الأنسولين.</strong></li><li><strong>مضادات الذهان.</strong></li><li><strong>مدرات البول.</strong></li><li><strong>بروبنسيد</strong> ( والذي يستخدم في علاج النقرس).</li><li><strong>سيمتيدين:</strong> و الذي يستخدم في علاج قرحة&nbsp; الجهاز الهضمي وحرقة الفؤاد.</li></ul><p>يجب توخي الحذر عند تناول أي من هذه العلاجات مع أقراص ليفوكس.</p><p>قد يضطر الطبيب المعالج لخفض الجرعة العلاجية من ليفوكس إذا كانت لديك مشاكل بالكلى.</p><p>&nbsp;</p><p>لا تتناول أقراص ليفوكس في نفس الوقت مع الأدوية التالية. يجب تناول ليفوكس إما قبل ساعتين من تناول هذه الأدوية أو بعد ساعتين من تناول هذه الأدوية:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الحديد (لعلاج الأنيميا)،العلاج بالفيتامينات المتعددة، أو المستحضرات الأخرى التي تحتوي على المغنيسيوم، الألومينيوم، الحديد أو الزنك.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة التي تحتوي على المغيسيوم أو الألومينيوم ( لعلاج الحموضة أو حرقة الفؤاد).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكرلفات ( لعلاج القرحة المعدية).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديدانوسين مضاد للفيروسات يستخدم في علاج فيروس نقص المناعة البشرية&nbsp;</p><p>هذا لأنها تؤثر على طريقة عمل ليفوكس.</p><p>اختبارات تحري الأفيونات في البول:</p><p>قد يؤدي استخدام ليفوكس أقراص لظهور نتائج إيجابية كاذبة لاختبارات تحري الأفيونات في البول وهي مسكنات قوية للآلام. يجب أن تخبر الطبيب بأنك تتناول أقراص ليفوكس في حالة ما إذا طلب منك إجراء اختبار البول.</p><p><strong>&nbsp;</strong></p><p><strong>د</strong><strong>- </strong><strong>&nbsp;</strong><strong>الحمل</strong><strong> </strong><strong>والرضاعة:</strong></p><p>لا تتناولي هذا الدواء إذا:</p><ul><li>كنت حاملا أو من المحتمل أن تكوني حاملا أو في حالة التفكير في الحمل.</li><li>إذا كنت تقومين بالرضاعة الطبيعية أو تخططين للقيام بالرضاعة الطبيعية.</li></ul><p>اسألي الطبيب المعالج أو الصيدلي قبل تناول أي دواء إذا كنت حاملا أو تقومين بالرضاعة الطبيعية.</p><p><strong>هـ</strong><strong>- </strong><strong>&nbsp;</strong><strong>تأثير</strong><strong> </strong><strong>ليفوكس</strong><strong> </strong><strong>على</strong><strong> </strong><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات:</strong></p><p>قد تحدث لك بعض الآثار الجانبية عند تناول هذا الدواء مثل الإحساس بالدوخة، الرغبة في النوم، أو الإحساس بالدوار أو تغير في قدرتك على الإبصار.&nbsp; وقد تؤثر هذه الآثار الجانبية على قدرتك على التركيز و سرعة رد فعلك. وفي حالة حدوث هذه الأعراض لا تقم بالقيادة ولا تقم بأي أعمال تتطلب درجة عالية من الانتباه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب تناول أقراص ليفوكس حسب تعليمات الطبيب المعالج.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول هذا الدواء عن طريق الفم.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويتم بلع الأقراص مع كمية مناسبة من الماء.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول أقراص ليفوكس مع أو بدن تناول الطعام.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يقوم الطبيب المعالج بتحديد كمية أقراص ليفوكس التي يجب أن تتناولها.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتعتمد الجرعة التي يتم تناولها على نوع العدوى البكتيرية الذي تعاني منه ومكان هذه العدوى.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتعتمد فترة العلاج على مدى خطورة العدوى لديك</p><p><strong>المرضى من البالغين وكبار السن&nbsp; ذوي وظائف كلوية طبيعية:</strong></p><p><strong>التهاب الجيوب الأنفية البكتيري الحاد:</strong></p><ul><li>500 ملجم مرة واحدة يوميا لمدة 10-14 يوم.&nbsp;</li><li>&nbsp;750ملجم مرة واحدة يوميا لمدة 5 أيام.</li></ul><p><strong>الالتهاب الرئوي</strong></p><p><strong>الالتهاب الرئوي المكتسب في المستشفى:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 750ملجم مرة واحدة يوميا لمدة 7-14 يوم</p><p><strong>الالتهاب الرئوي المكتسب من المجتمع:</strong></p><ul><li>500 ملجم مرة واحدة يوميا لمدة 10-14 يوم.&nbsp;</li><li>&nbsp;750ملجم مرة واحدة يوميا لمدة 5 أيام.</li></ul><p><strong>الاشتداد الحاد لالتهاب القصبات المزمن:</strong></p><ul><li>500ملجم مرة واحدة يوميا لمدة 7 أيام</li></ul><p><strong>عدوى السبيل البولي المصحوبة بمضاعفات أو التهاب الحويضة والكلية الحاد:</strong></p><ul><li>750ملجم مرة واحدة يوميا لمدة 5 أيام.</li><li>250ملجم مرة واحدة يوميا لمدة 10 أيام.</li></ul><p><strong>عدوى السبيل البولي الغير مصحوبة بمضاعفا</strong>ت:</p><ul><li>250ملجم مرة واحدة يوميا لمدة 3 أيام.</li></ul><p><strong>التهاب البروستاتا البكتيري المزمن:</strong></p><ul><li>500 ملجم مرة واحدة يوميا لمدة 28 يوم.&nbsp;</li></ul><p><strong>التهاب الجلد </strong><strong>و الأنسجة تحت الجلد</strong><strong> البكتيري المصحوب بمضاعفات:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 750ملجم مرة واحدة يوميا لمدة 7-14 يوم</p><p><strong>التهاب الجلد </strong><strong>و الأنسجة تحت الجلد</strong><strong> البكتيري الغير مصحوب بمضاعفات:</strong></p><p>500 ملجم مرة واحدة يوميا لمدة 7-10 أيام.&nbsp;</p><p><strong>المرضى من البالغين الذين يعانون من مشاكل بالكلى:</strong></p><p>يجب على الطبيب المعالج تقليل الجرعة للمرضى الذين يعانون من مشاكل بالكلى.</p><p><strong>المرضى من الأطفال والمراهقين:</strong></p><p>لايوصف هذا الدواء للمرضى من الأطفال والمراهقين الذين يقل عمرهم عن 18 عاما.</p><p>إن الأطفال هم أكثرعرضة لحدوث مشاكل بالعظام ، المفاصل أو الأوتار&nbsp; مثل الألم أو التورم وذلك عند تناول ليفوفلوكساسين.</p><p><strong>إذا تم وصف ليفوكس لك بعد تعرضك للجمرة الخبيثة تكون الجرعة كالتالي:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 ملجم&nbsp; مرة واحدة يوميا لمدة 60 يوما و ذلك في المرضى من البالغين والأطفال الذين يكون عمرهم 6 أشهر أو أكثر ويزيد وزنهم عن 50 كجم.</p><p>ويصرح باستخدام ليفوكس للتقليل من احتمالية الإصابة بالجمرة الخبيثة أو لتقليل احتمالية زيادة المرض سوءا و ذلك عند تعرضك لجرثومة الجمرة الخبيثة.</p><p>يجب أن تتناول ليفوكس حسب تعليمات الطبيب المعالج. لا تتوقف عن استخدام ليفوكس بدون استشارة الطبيب المعالج. إن التوقف عن استخدام ليفوكس قبل نهاية المدة المحددة&nbsp; قد يؤدي إلى تعرضك للإصابة بمرض الجمرة الخبيثة.&nbsp;</p><p>إن مدى أمان استخدام ليفوكس لمدة تزيد عن 28 يوما&nbsp; في المرضى البالغين أومدة تزيد عن 14 يوما في الأطفال الذين يكون عمرهم 6 أشهر أو أكثر ليس معروفا.</p><p>إذا كنت حاملا أو تخططين لحدوث حمل أثناء تناولك ليفوكس ، فيجب أن تحددي مع الطبيب المعالج إذا ما كانت الفوائد المرجوة من تناول ليفوكس &nbsp;في حالة الجمرة الخبيثة أهم من المخاطر المحتملة.</p><p>في الأطفال الذين يكون عمرهم 6 أشهر أو أكثر و تعرضوا لاستنشاق جرثومة الجمرة الخبيثة:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم ليفوكس لمنع حدوث مرض الجمرة الخبيثة(الجمرة الخبيثة الاستنشاقية)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليس من المعروف مدى أمان استخدام ليفوكس أقراص في الأطفال الذين يقل عمرهم عن 6 أشهر.</p><p><strong>أ</strong><strong> - </strong><strong>الجرعة</strong><strong> </strong><strong>الزائدة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>ليفوكس</strong></p><p>إذا تناولت عددا من أقراص ليفوكس أكثر من الموصوف لك، استشر الطبيب المعالج أو الجأ إلى مساعدة طبية في الحال. خذ معك علبة الدواء لكي يتكمن الطبيب من معرفة الدواء الذي تناولته.&nbsp; قد تحدث بعض التأثيرات التالية: تشنجات أو نوبات عصبية، الإحساس بالارتباك، دوخة ، نقص الوعي والإدراك، ومشاكل في القلب تؤدي إلى اضطراب في ضربات القلب والإحساس بالغثيان.</p><p><strong>ب</strong><strong> - </strong><strong>نسيان</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>ليفوكس</strong></p><p>إذا نسيت تناول جرعة من أقراص ليفوكس ، تناول الجرعة حالما تذكرت إلا إذا كان موعد الجرعة التي تليها قد أوشك.&nbsp; في هذه الحالة، لا تنناول الجرعة مضاعفة.</p><p><strong>ج</strong><strong> - </strong><strong>التوقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>ليفوكس</strong></p><p>لاتتوقف عن تناول أقراص ليفوكس لمجرد الإحساس بتحسن حالتك، فمن المهم أن تتم مدة العلاج المحددة لك من قبل الطبيب المعالج. إن التوقف عن استخدام ليفوكس قبل نهاية المدة المحددة&nbsp; قد يؤدي إلى تعرضك للإصابة بالمرض مرة أخرى&nbsp; وقد تسوء حالتك أو قد تتكون للبكتريا المسببة للمرض مناعة ضد العلاج.</p><p>إذا كانت لديك أي أسئلة أو استفسارات أخرى ، استشر الطبيب المعالج أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية الأخرى، قد يسبب ليفوكس أعراض جانبية&nbsp; عند استخدامه، وبالرغم من ذلك&nbsp; ليس من الضروري أن تظهر هذه الأعراض في جميع المرضى الذين يستخدمون ليفوكس. وتكون معظم هذه الأعراض خفيفة إلى متوسطة&nbsp; وتختفي بعد فترة قصيرة.</p><p><strong>توقف عن تناول ليفوكس وتوجه لزيارة الطبيب في الحال إذا ظهر عليك أي من الأعراض التالية:</strong></p><p><strong>نادرة الحدوث جدا ( &gt; 1/ 10000 ):</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تفاعلات أرجية ، حتى بعد تناول جرعة واحدة من العلاج.&nbsp; وقد تشمل العلامات حدوث طفح جلدي، مشاكل في البلع أو التنفس، شرى، بحة في الصوت، تسارع ضربات القلب، إغماء، و تورم في الشفتين، الوجه، الحلق، أو اللسان.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إحساس بالحرقان، وخز، ألم، ضعف و تنميل في الذراعين، اليدين، الأرجل أو الأقدام. قد تكون هذه علامات لما يسمى باعتلال الأعصاب.&nbsp; يجب اللجوء إلى الطبيب المعالج في الحال&nbsp; إذا ظهرت عليك أي من هذه الأعراض الجانبية</p><p>&nbsp;<strong>نادرة الحدوث ( &gt; 1/ 1000 ):</strong></p><ul><li>عدوى جرثومية بالمعي ( التهاب القولون الغشائي الكاذب):</li></ul><p>إسهال مائي، إسهال مستمر أو مصحوبا بالدم، بالإضافة إلى تقلص بالمعدة وارتفاع درجة الحرارة. قد تكون هذه&nbsp; علامات لمشاكل خطيرة بالأمعاء.</p><ul><li>ألم والتهاب بالأوتار. ويعتبر وتر أخيليس الأكثر تعرضا لهذه الحالة وقد يتعرض الوتر في بعض الأحيان إلى التمزق.</li><li>نوبات عصبية ( تشنجات).</li></ul><p><strong>أخرى:</strong></p><ul><li>طفح جلدي شديد الخطورة ويشمل تكون حويصلات، تقشر بالجلد حول الشفتين ، العين، الفم، الأنف، والأعضاء التناسلية.</li><li>فقدان الشهية، تغير لون الجلد والعينين إلى اللون الأصفر، تحول لون البول إلى اللون الداكن، حكة، أو ألم بالمعدة( البطن). قد تكون هذه علامات لمشاكل في الكبد.</li></ul><p><strong>استشر الطبيب المعالج إذا ازدادت الأعراض الجانبية التالية سوءا أو إذا استمرت لعدة أيام:</strong></p><p><strong>شائعة (&gt;1/10 ):</strong></p><ul><li>غثيان وإسهال</li><li>زيادة مستوى إنزيمات الكبد في الدم.</li><li>صداع، دوخة</li><li>أرق.</li></ul><p><strong>غير شائعة (&gt;1/100 ):</strong></p><ul><li>حكة، و طفح جلدي</li><li>فقدان الشهية، اضطرابات بالمعدة (عسر هضم)، قيء أو ألم في منطقة المعدة، انتفاخ أو إمساك.</li><li>دوار ، الإحساس بالنعاس، اضطرابات في النوم أو الإحساس بالعصبية.</li><li>ضعف عام.</li></ul><p>&nbsp;</p><p><strong>نادرة الحدوث (&gt;1/1000 ):</strong></p><ul><li>الإحساس بالنخز في اليدين والأرجل ( مذل) أو رعشة.</li><li>قلق، إكتئاب، مشاكل نفسية، هياج أو اضطراب.</li><li>تسارع في ضربات القلب بصورة غير اعتيادية أو انخفاض في ضغط الدم.</li><li>آلام بالمفاصل أو العضلات.</li><li>كدمات و سهولة النزف والتي ترجع إلى نقص في الصفائح الدموية.</li><li>نقص في عدد خلايا الدم البيضاء(يسمى قلة العدلات).</li><li>صعوبة أو أزيز أثناء التنفس (تشنج قصبي).</li><li>حدوث حكة بصورة شديدة أو شرى.</li></ul><p><strong>نادرة الحدوث جدا (&gt;1/10000)</strong></p><ul><li>زيادة تحسس الجلد لأشعة الشمس وللأشعة فوق البنفسجية.</li><li>نقص في مستوى السكر بالدم وارتفاع مستوى السكر بالدم. إن هذه الأعراض مهمة لمرضى السكري.</li><li>مشاكل في السمع أو الإبصار أو تغير في حاستي التذوق و الشم.</li><li>رؤية أو سمع أشياء غير موجودة ( هلاوس)، تغير في الرأي أو طريقة التفكير ( تفاعلات نفسية) مع وجود فرصة لحدوث أفكار انتحارية .</li><li>خلل بالدورة الدموية (صدمة شبيهة بالتأقية).</li><li>وهن بالعضلات. ويعتبر هذا العرض مهما في حالة المرضى المصابين بمرض الوهن العضلي الوبيل وهو مرض نادر يصيب الجهاز العصبي.</li><li>التهاب بالكبد، خلل في وظيفة الكلى وفي بعض الأحيان فشل كلوي والذي قد يكون بسبب تفاعل أرجي بالكلى يسمى التهاب الكلية الخلالي.</li><li>حمى، التهاب الحلق، وشعور عام بالاعتلال بصورة مستمرة ولا تختفي . قد يكون ذلك بسبب انخفاض عدد خلايا الدم البيضاء.</li><li>حمى و تفاعلات أرجية بالرئة.</li></ul><p><strong>أعراض جانبية أخرى تشمل:</strong></p><ul><li>انخفاض عدد خلايا الدم الحمراء ( أنيميا). وقد تؤدي هذه الحالة إلى تغير لون الجلد إلى اللون الشاحب أو الأصفر وذلك بسبب الضرر الذي يصيب خلايا الدم الحمراء وانخفاض عدد جميع خلايا الدم.</li><li>فرط الاستجابة المناعية ( فرط التحسس).</li><li>فرط التعرق.</li><li>آلام و تشمل آلام بالظهر والصدر والأطراف.</li><li>صعوبة في الحركة والمشي.</li><li>نوبات البرفيرية في المرضى الذين يعانون من مرض البرفيرية.</li><li>التهاب في الأوعية الدموية بسبب تفاعلات أرجية.</li></ul><p>استشر الطبيب المعالج أو الصيدلي اذا ازدادت الأعراض الجانبية سوءاً أو إذا لاحظت أي أعراض جانبية أخرى غير مذكورة بهذه النشرة الطبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>يحفظ بعيدا عن متناول الأطفال.</li><li>يحفظ في درجة حرارة أقل من 30 درجة مئوية في عبوته الأصلية.</li><li>لا تستخدم ليفوكس بعد انتهاء تاريخ الصلاحية المدون على العبوة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة ليفوفلوكساسين. يحتوي كل قرص من ليفوكس 250 ملجم أقراص على 250 ملجم من مادة ليفوفلوكساسين، يحتوي كل قرص من ليفوكس 500 ملجم أقراص على 500 ملجم من مادة ليفوفلوكساسين، يحتوي كل قرص من ليفوكس 750 ملجم أقراص على 750 ملجم من مادة ليفوفلوكساسين.</p><p>المواد الغير فعالة بالقرص: هيدروكسي بروبايل ميثيل سيلليلوز، كروسبوفيدون، مايكروكريستالين سيلليلوز مضاف إليها السيليكا، ستيارات المغنيسيوم.</p><p>الطبقة المغلفة: بولي سوربات 80، ثاني أكسيد التيتانيوم، تالك نقي، بولي إيثيلين جليكول، هيدروكسي بروبايل ميثيل سيلليلوز، أكسيد الحديد الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أقراص ليفوكس هي أقراص مغلفة بطبقة رقيقة  للتناول عن طريق الفم وهي أقراص مستطيلة لونها أصفر فاتح.
يتوفر ليفوكس 250، 500، 750ملجم في عبوات تحتوي على 5 أقراص.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج <strong>الدوائية</strong></p><p>مصنع الأدوية بالقصيم،</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية،</p><p>المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2011.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levox 250 mg tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet of Levox contains levofloxacin hemihydrate corresponding to
250 mg of levofloxacin.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shape: Oblong, Biconvex film coated tablet, plain surface on both sides.
Color: Light Yellow.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; In adults with infections of mild or moderate severity, Levox tablets are indicated for<br />the treatment of the following infections when due to levofloxacin-susceptible<br />microorganisms:<br />&bull; Acute bacterial sinusitis (adequately diagnosed according to national and/or local<br />guidelines on the treatment of respiratory tract infections)<br />&bull; Acute bacterial exacerbations of chronic bronchitis (adequately diagnosed according to<br />national and/or local guidelines on the treatment of respiratory tract infections)<br />&bull; Community-acquired pneumonia<br />&bull; Uncomplicated urinary tract infections<br />&bull; Complicated urinary tract infections including pyelonephritis<br />&bull; Chronic bacterial prostatitis.<br />&bull; Skin and soft tissue infections.<br />Before prescribing Levox, consideration should be given to national and/or local guidance<br />on the appropriate use of fluoroquinolones.<br />- Not recommended for children under 12 years.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Levox tablets are administered once or twice daily. The dosage depends on the type and</p><p>severity of the infection and the sensitivity of the presumed causative pathogen.<br /><em><strong>&bull; Duration of treatment</strong></em><br />The duration of treatment varies according to the course of the disease (see table below).<br />As with antibiotic therapy in general, administration of Levox tablets should be continued<br />for a minimum of 48 to 72 hours after the patient has become afebrile or evidence of<br />bacterial eradication has been obtained.<br /><em><strong>&bull; Method of administration</strong></em><br />Levox tablets should be swallowed without crushing and with sufficient amount of liquid.<br />The tablets may be taken during meals or between meals. Levox tablets should be taken at<br />least two hours before or after iron salts, antacids and sucralfate administration since<br />reduction of absorption can occur (see section 4.5).<br /><strong>Inhalation anthrax (post exposure)</strong><br />The effectiveness of Levox&reg; for this indication is based on plasma concentrations achieved in<br />humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levox&reg; has not been<br />tested in humans for the post-exposure prevention of inhalation anthrax. The mean plasma<br />concentrations of Levox&reg; associated with a statistically significant improvement in survival<br />over placebo in the rhesus monkey model of inhalational anthrax are reached or exceeded in<br />adult and pediatric patients receiving the recommended oral and intravenous dosage regimens<br />Levofloxacin pharmacokinetics have been evaluated in adult and pediatric patients. The mean<br />(&plusmn; SD) steady state peak plasma concentration in human adults receiving 500 mg orally or<br />intravenously once daily is 5.7 &plusmn; 1.4 and 6.4 &plusmn; 0.8 mcg/mL, respectively; and the<br />corresponding total plasma exposure (AUC0&ndash;24) is 47.5 &plusmn; 6.7 and 54.6 &plusmn; 11.1 mcg.h/mL,<br />respectively. The predicted steady-state pharmacokinetic parameters in pediatric patients<br />ranging in age from 6 months to 17 years receiving 8 mg/kg orally every 12 hours (not to<br />exceed 250 mg per dose) were calculated to be comparable to those observed in adults<br />receiving 500 mg orally once daily.<br />In adults, the safety of Levox&reg; for treatment durations of up to 28 days is well characterized.<br />However, information pertaining to extended use at 500 mg daily up to 60 days is limited.<br />Prolonged Levox&reg; therapy in adults should only be used when the benefit outweighs the risk.<br />In pediatric patients, the safety of levofloxacin for treatment durations of more than 14 days<br />has not been studied. An increased incidence of musculoskeletal adverse events (arthralgia,<br />arthritis, tendonopathy, gait abnormality) compared to controls has been observed in clinical<br />studies with treatment duration of up to 14 days. Long-term safety data, including effects on<br />cartilage, following the administration of levofloxacin to pediatric patients is limited.<br /><strong><u>Posology</u><br />The following dose recommendations can be given for Levox:<br />Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose regimen</strong></p><p><strong><em>(according to severity)</em></strong></p></td><td style="vertical-align:top"><p><strong>Duration of treatment</strong></p><p><strong><em>(according to severity)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute&nbsp;sinusitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>10 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute&nbsp; exacerbations of chronic bronchitis</p></td><td style="vertical-align:top"><p>250 to 500 mg once daily</p></td><td style="vertical-align:top"><p>7 - 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Community-acquired pneumonia</p></td><td style="vertical-align:top"><p>500 mg once or twice daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated urinary tract infection</p></td><td style="vertical-align:top"><p>250 mg once daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections&nbsp;including pyelonephritis</p></td><td style="vertical-align:top"><p>250 mg once daily</p></td><td style="vertical-align:top"><p>7 - 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Chronic bacterial prostatitis.</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>Skin and soft tissue infections</p></td><td style="vertical-align:top"><p>250 mg once daily or 500 mg<br />once or twice daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr></tbody></table><p><strong><u>Special populations</u><br />Impaired renal function (creatinine clearance &le;50ml/min)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p><strong>Dose regimen</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>250 mg/24 h</strong></p></td><td style="vertical-align:top"><p><strong>500 mg/24 h</strong></p></td><td style="vertical-align:top"><p><strong>500 mg/12 h</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Creatinine clearance</strong></p></td><td style="vertical-align:top"><p><em>first dose:</em>&nbsp;250 mg</p></td><td style="vertical-align:top"><p><em>first dose:</em>&nbsp;500 mg</p></td><td style="vertical-align:top"><p><em>first dose:</em>&nbsp;500 mg</p></td></tr><tr><td style="vertical-align:top"><p>50-20 ml/min</p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/24 h</p></td><td style="vertical-align:top"><p><em>then</em>&nbsp;: 250 mg/24 h</p></td><td style="vertical-align:top"><p><em>then</em>&nbsp;: 250 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>19-10 ml/min</p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/48 h</p></td><td style="vertical-align:top"><p><em>then</em>&nbsp;: 125 mg/ 24 h</p></td><td style="vertical-align:top"><p><em>then</em>&nbsp;: 125 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10 ml/min</p><p>(including haemodialysis and CAPD)&nbsp;<sup>1</sup></p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/48 h</p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/24 h</p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/24 h</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).</p><p>Impaired liver function<br />No adjustment of dosage is required since levofloxacin is not metabolised to any relevant<br />extent by the liver and is mainly excreted by the kidneys.<br />In the elderly<br />No adjustment of dosage is required in the elderly, other than that imposed by consideration of<br />renal function. (See section 4.4 QT interval prolongation).<br />In children<br />Levox is contraindicated in children and growing adolescents (see section 4.3).<br /><strong>Inhalational Anthrax (Post-Exposure)</strong><br />Levofloxacin is indicated in pediatric patients for inhalational anthrax (post-exposure). The<br />risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is</p><p>appropriate. The safety of levofloxacin in pediatric patients treated for more than 14 days has<br />not been studied. The pharmacokinetics of levofloxacin following a single intravenous dose<br />were investigated in pediatric patients ranging in age from six months to 16 years. Pediatric<br />patients cleared levofloxacin faster than adult patients resulting in lower plasma exposures than<br />adults for a given mg/kg dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levox tablets must not be used:
• In patients hypersensitive to levofloxacin or other quinolones or any of the excipients,
• In patients with epilepsy,
• In patients with history of tendon disorders related to fluoroquinolone administration,
• In children or growing adolescents,
• During pregnancy,
• In breast-feeding women.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the most severe cases of pneumococcal pneumonia Levox may not be the optimal therapy.<br />Nosocomial infections due to P. aeruginosa may require combination therapy.<br /><strong><em>Tendinitis and tendon rupture</em></strong><br />Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to<br />tendon rupture. The risk of tendinitis and tendon rupture is increased in the elderly and in<br />patients using corticosteroids. Close monitoring of these patients is therefore necessary if they<br />are prescribed Levox. All patients should consult their physician if they experience symptoms<br />of tendinitis. If tendinitis is suspected, treatment with Levox must be halted immediately, and<br />appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon.<br /><em><strong>Clostridium difficile-associated disease</strong></em><br />Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with Levox<br />tablets, may be symptomatic of Clostridium difficile-associated disease, the most severe form<br />of which is pseudomembranous colitis. If pseudomembranous colitis is suspected, Levox<br />tablets must be stopped immediately and patients should be treated with supportive measures &plusmn;<br />specific therapy without delay (e.g. oral vancomycin). Products inhibiting the peristalsis are<br />contraindicated in this clinical situation.<br /><em><strong>Patients predisposed to seizures</strong></em><br />Levox tablets are contraindicated in patients with a history of epilepsy and, as with other<br />quinolones, should be used with extreme caution in patients predisposed to seizures, such as<br />patients with pre-existing central nervous system lesions, concomitant treatment with fenbufen<br />and similar non-steroidal anti-inflammatory drugs or with drugs which lower the cerebral</p><p>seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures,<br />treatment with levofloxacin should be discontinued.<br /><strong><em>Patients with G-6- phosphate dehydrogenase deficiency</em></strong><br />Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be<br />prone to haemolytic reactions when treated with quinolone antibacterial agents, and so<br />levofloxacin should be used with caution.<br /><strong><em>Patients with renal impairment</em></strong><br />Since levofloxacin is excreted mainly by the kidneys, the dose of Levox should be adjusted in<br />patients with renal impairment (see section 4.2).<br /><strong><em>Hypersensitivity reactions</em></strong><br />Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up<br />to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should<br />discontinue treatment immediately and contact their physician or an emergency physician, who<br />will initiate appropriate emergency measures.<br /><strong><em>Hypoglycemia</em></strong><br />As with all quinolones, hypoglycemia has been reported, usually in diabetic patients receiving<br />concomitant treatment with an oral hypoglycemic agent (e.g., glibenclamide) or with insulin. In<br />these diabetic patients, careful monitoring of blood glucose is recommended. (See section 4.8).<br /><strong><em>Prevention of photosensitisation</em></strong><br />Although photosensitisation is very rare with levofloxacin, it is recommended that patients<br />should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g.<br />sunray lamp, solarium), in order to prevent photosensitisation.<br /><strong><em>Patients treated with Vitamin K antagonists</em></strong><br />Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with<br />Levox in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be<br />monitored when these drugs are given concomitantly (see section 4.5).<br /><em><strong>Psychotic reactions</strong></em><br />Psychotic reactions have been reported in patients receiving quinolones, including<br />levofloxacin. In very rare cases these have progressed to suicidal thoughts and selfendangering<br />behaviour- sometimes after only a single dose of levofloxacin (see section 4.8). In<br />the event that the patient develops these reactions, levofloxacin should be discontinued and<br />appropriate measures instituted. Caution is recommended if levofloxacin is to be used in<br />psychotic patients or in patients with history of psychiatric disease.<br /><em><strong>QT interval prolongation</strong></em><br />Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with<br />known risk factors for prolongation of the QT interval such as, for example:<br />- Congenital long QT syndrome<br />- Concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III<br />antiarrhythmics, tricyclic antidepressants, macrolides).<br />- Uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia)<br />- Elderly<br />- Cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)<br />(See section 4.2 Elderly, section 4.5, section 4.8, section 4.9).</p><p><strong><em>Peripheral neuropathy</em></strong><br />Sensory or sensorimotor peripheral neuropathy has been reported in patients receiving<br />fluoroquinolones, including levofloxacin, which can be rapid in its onset. Levofloxacin should<br />be discontinued if the patient experiences symptoms of neuropathy in order to prevent the<br />development of an irreversible condition.<br /><em><strong>Opiates</strong></em><br />In patients treated with levofloxacin, determination of opiates in urine may give false-positive<br />results. It may be necessary to confirm positive opiate screens by more specific method.<br /><em><strong>Hepatobiliary disorders</strong></em><br />Cases of hepatic necrosis up to life threatening hepatic failure have been reported with<br />levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8).<br />Patients should be advised to stop treatment and contact their doctor if signs and symptoms of<br />hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.<br />Levox&reg; is indicated in pediatric patients (&ge;6 months of age) only for the prevention of<br />inhalational anthrax (post-exposure). An increased incidence of musculoskeletal disorders<br />(arthralgia, arthritis, tendonopathy, and gait abnormality) compared to controls has been<br />observed in pediatric patients receiving Levox&reg;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effect of other medicinal products on Levox<br /><em>Iron salts, magnesium- or aluminium-containing antacids</em></strong><br />Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminiumcontaining<br />antacids are administered concomitantly with Levox tablets. It is recommended that<br />preparations containing divalent or trivalent cations such as iron salts, or magnesium- or<br />aluminium-containing antacids should not be taken 2 hours before or after Levox tablet<br />administration (see section 4.2). No interaction was found with calcium carbonate.<br /><em><strong>Sucralfate</strong></em><br />The bioavailability of Levox tablets is significantly reduced when administered together with<br />sucralfate. If the patient is to receive both sucralfate and Levox, it is best to administer<br />sucralfate 2 hours after the Levox tablet administration (see section 4.2).<br /><em><strong>Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs</strong></em><br />No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical<br />study. However a pronounced lowering of the cerebral seizure threshold may occur when<br />quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or<br />other agents, which lower the seizure threshold.<br />Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when<br />administered alone.<br /><em><strong>Probenecid and cimetidine</strong></em><br />Probenecid and cimetidine had a statistically significant effect on the elimination of<br />levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and<br />probenecid (34%). This is because both drugs are capable of blocking the renal tubular</p><p>secretion of levofloxacin. However, at the tested doses in the study, the statistically significant<br />kinetic differences are unlikely to be of clinical relevance.<br />Caution should be exercised when levofloxacin is coadministered with drugs that affect the<br />tubular renal secretion such as probenecid and cimetidine, especially in renally impaired<br />patients.<br /><em><strong>Other relevant information</strong></em><br />Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not<br />affected to any clinically relevant extent when levofloxacin was administered together with the<br />following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.<br /><strong>Effect of Levox on other medicinal products<br /><em>Ciclosporin</em></strong><br />The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.<br /><strong><em>Vitamin K antagonists</em></strong><br />Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been<br />reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g.<br />warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K<br />antagonists (see section 4.4).<br /><strong><em>Drugs known to prolong QT interval</em></strong><br />Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving<br />drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic<br />antidepressants, macrolides). (See section 4.4 QT interval prolongation).<br /><strong>Other forms of interactions<br /><em>Meals</em></strong><br />There is no clinically relevant interaction with food. Levox tablets may therefore be<br />administered regardless of food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><em><strong>Pregnancy</strong></em><br />Reproductive studies in animals did not raise specific concern. However, in the absence of<br />human data and due to the experimental risk of damage by fluoroquinolones to the weightbearing<br />cartilage of the growing organism, Levox tablets must not be used in pregnant women.<br />(see sections 4.3 and 5.3)<br /><em><strong>Lactation</strong></em><br />In the absence of human data and due to the experimental risk of damage by fluoroquinolones<br />to the weight-bearing cartilage of the growing organism, Levox tablets must not be used in<br />breast-feeding women. (see sections 4.3 and 5.3)</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, and visual disturbances) may<br />impair the patient&#39;s ability to concentrate and react, and therefore may constitute a risk in<br />situations where these abilities are of special importance (e.g. driving a car or operating<br />machinery).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies on Levofloxacin in more<br />than 5000 patients and on extensive post marketing experience.<br />The adverse reactions are described according to the MedDRA system organ class below.<br />Frequencies are defined using the following convention: very common (<strong>&ge;</strong> 1/10), common (<strong>&ge;</strong><br />1/100, &lt;1/10), uncommon (<strong>&ge;</strong> 1/1000, &le;1/100), rare ( <strong>&ge;</strong>1/10000, &le;1/1000), very rare (<br />1/10000), not known (cannot be estimated from the available data).<br />Within each frequency grouping, undesirable effects are presented in order of decreasing<br />seriousness.<br /><strong>Infections and infestations</strong><br />Uncommon: Fungal infection (and proliferation of other resistant microorganisms)<br /><strong>Blood and lymphatic system disorders</strong><br />Uncommon: Leukopenia, eosinophilia<br />Rare: Thrombocytopenia, neutropenia<br />Very rare: Agranulocytosis<br />Not Known: Pancytopenia, haemolytic anaemia<br /><strong>Immune system disorders</strong><br />Very rare: Anaphylactic shock (see section 4.4)<br />Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose<br />Not known: Hypersensitivity (see section 4.4)<br /><strong>Metabolism and nutrition disorders</strong><br />Uncommon: Anorexia<br />Very rare: Hypoglycemia, particularly in diabetic patients (see section 4.4)<br /><strong>Psychiatric disorders</strong><br />Uncommon: Insomnia, nervousness<br />Rare: Psychotic disorder, Depression, confusional state, agitation, anxiety<br />Very rare: Psychotic reactions with self-endangering behaviour including suicidal ideation or<br />acts (see section 4.4), hallucination<br /><strong>Nervous system disorders</strong><br />Uncommon: Dizziness, headache, somnolence<br />Rare: Convulsion, tremor, paraesthesia,<br />Very rare: sensory or sensorimotor peripheral neuropathy, dysgeusia including ageusia,<br />parosmia including anosmia<br /><strong>Eye disorders</strong><br />Very rare: Visual disturbance<br /><strong>Ear and Labyrinth disorders</strong><br />Uncommon: Vertigo<br />Very rare: Hearing impaired<br />Not known: Tinnitus<br /><strong>Cardiac disorders</strong><br />Rare: Tachycardia<br />Not Known: Electrocardiogram QT prolonged (see section 4.4 QT interval prolongation and<br />section 4.9)</p><p><strong>Vascular disorders</strong><br />Rare: Hypotension<br /><strong>Respiratory, thoracic and mediastinal disorders</strong><br />Rare: Bronchospasm, dyspnoea<br />Very rare: Pneumonitis allergic<br /><strong>Gastrointestinal disorders</strong><br />Common: Diarrhoea, nausea<br />Uncommon: Vomiting, abdominal pain, dyspepsia, flatulence, constipation<br />Rare: Diarrhoea &ndash;haemorrhagic, which in very rare cases may be indicative of enterocolitis,<br />including pseudomembranous colitis<br /><strong>Hepatobiliary disorders</strong><br />Common: Hepatic enzyme increased (ALT/AST, alkaline phosphatase, GGT)<br />Uncommon: Blood bilirubin increased<br />Very rare: Hepatitis<br />Not known: Jaundice and severe liver injury, including cases with acute liver failure, has been<br />reported with levofloxacin, primarily in patients with severe underlying diseases (see section<br />4.4).<br /><strong>Skin and subcutaneous tissue disorders</strong><br />Uncommon: Rash, pruritus<br />Rare: Urticaria<br />Very rare: Angioneurotic oedema, photosensitivity reaction<br />Not Known: Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme,<br />hyperhidrosis<br />Mucocutaneous reactions may sometimes occur even after the first dose<br /><strong>Musculoskeletal and Connective tissue disorders</strong><br />Rare: Tendon disorder (see section 4.4) including tendinitis (e.g. Achilles tendon), arthralgia,<br />myalgia<br />Very rare: Tendon ruptures (see section 4.4). This undesirable effect may occur within 48<br />hours of starting treatment and may be bilateral, muscular weakness which may be of special<br />importance in patients with myasthenia gravis<br />Not Known: Rhabdomyolysis<br /><strong>Renal and urinary disorders</strong><br />Uncommon: Blood creatinine increased<br />Very rare: Renal failure acute (e.g. due to nephritis interstitial)<br /><strong>General disorders and administration site conditions</strong><br />Uncommon: Asthenia<br />Very rare: Pyrexia<br />Not known: Pain (including pain in back, chest, and extremities)<br />Other undesirable effects that have been associated with fluoroquinolone administration<br />include:<br />&bull; Extrapyramidal symptoms and other disorders of muscular coordination,<br />&bull; Hypersensitivity vasculitis,<br />&bull; Attacks of porphyria in patients with porphyria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with<br />supra-therapeutic doses, the most important signs to be expected following acute overdosage of<br />Levofloxacin tablets are central nervous system symptoms such as confusion, dizziness,<br />impairment of consciousness, and convulsive seizures, increases in QT interval as well as<br />gastro-intestinal reactions such as nausea and mucosal erosions.<br />In the event of overdose, symptomatic treatment should be implemented. ECG monitoring<br />should be undertaken, because of the possibility of QT interval prolongation. Antacids may be<br />used for protection of gastric mucosa. Haemodialysis, including peritoneal dialysis and CAPD,<br />are not effective in removing levofloxacin from the body. No specific antidote exists.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>- Anatomical Therapeutical Chemical (ATC): J01MA12.<br /><em>- Pharmacotherapeutic group:</em></strong><br />Quinolone antibacterial, fluoroquinolones<br />Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-)<br />enantiomer of the racemic drug substance ofloxacin.<br /><em><strong>Mechanism of action</strong></em><br />As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex<br />and topoisomerase IV.<br /><em><strong>PK/PD relationship</strong></em><br />The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum<br />concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory<br />concentration (MIC).<br /><em><strong>Mechanism of resistance</strong></em><br />The main mechanism of resistance is due to a gyr-A mutation. In vitro, there is a crossresistance<br />between levofloxacin and other fluoroquinolones.<br />Due to the mechanism of action, there is generally no cross-resistance between levofloxacin<br />and other classes of antibacterial agents.<br /><em><strong>Breakpoints</strong></em><br />The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from<br />intermediately susceptible organisms and intermediately susceptible from resistant organisms<br />are presented in the below table for MIC testing (mg/L).<br />EUCAST clinical MIC breakpoints for levofloxacin (2006-06-20):</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriacae</p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>S.pneumoniae&nbsp;</em><em><sup>1</sup></em></p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus A,B,C,G</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>H.influenzae,&nbsp;M.catarrhalis</em><sup>2</sup></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<font size="1">3</font></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1 the S/I-breakpoint was increased from 1.0 to 2.0 to avoid dividing the wild type MIC<br />distribution. The breakpoints relate to high dose therapy.<br />2 Strains with MIC values above the S/I breakpoint are very rare or not yet reported. The<br />identification and antimicrobial susceptibility tests on any such isolate must be repeated and if<br />the result is confirmed the isolate sent to a reference laboratory.<br />3 Non-species related breakpoints have been determined mainly based on<br />pharmacokinetic/pharmacodynamic data and are independent of MIC distributions of specific<br />species. They are for use only for species that have not been given a species-specific<br />breakpoint and are not for use with species where susceptibility testing is not recommended or<br />for which there is insufficient evidence that the species in question is a good target<br />(Enterococcus, Neisseria, Gram negative anaerobes)</sup></p></td></tr></tbody></table><p>The CLSI (Clinical And Laboratory Standards Institute, formerly NCCLS) recommended MIC<br />breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms<br />and intermediately susceptible from resistant organisms are presented in the below table for<br />MIC testing (&mu;g/mL) or disc diffusion testing (zone diameter [mm] using a 5 &mu;g levofloxacin<br />disc).<br />CLSI recommended MIC and disc diffusion breakpoints for levofloxacin (M100-S17, 2007):</p><table border="1" cellspacing="1" cellpadding="1" style="width:531px"><tbody><tr><td style="width:180px">Pathogen</td><td style="width:164px">Susceptible</td><td style="width:186px">Resistant</td></tr><tr><td style="width:180px">Enterobacteriaceae</td><td style="width:164px">&le;2 &mu;g/mL<br /><strong>&ge;</strong>17 mm</td><td style="width:186px"><strong>&ge;</strong>8 &mu;g/mL<br />&le;13 mm</td></tr><tr><td style="width:180px">Non-Enterobacteriaceae.</td><td style="width:164px">&le;2 &mu;g/mL<br /><strong>&ge;</strong>17 mm</td><td style="width:186px"><strong>&ge;</strong>8 &mu;g/mL<br />&le;13 mm</td></tr><tr><td style="width:180px">Acinetobacter spp.</td><td style="width:164px">&le;2 &mu;g/mL<br /><strong>&ge;</strong>17 mm</td><td style="width:186px"><strong>&ge;</strong>8 &mu;g/mL<br />&le;13 mm</td></tr><tr><td style="width:180px">Stenotrophomonas<br />maltophilia</td><td style="width:164px">&le;2 &mu;g/mL<br /><strong>&ge;</strong>17 mm</td><td style="width:186px"><strong>&ge;</strong>8 &mu;g/mL<br />&le;13 mm</td></tr><tr><td style="width:180px">Staphylococcus spp.</td><td style="width:164px">&le;1 &mu;g/mL<br /><strong>&ge;</strong>19 mm</td><td style="width:186px"><strong>&ge;</strong>4 &mu;g/mL<br />&le;15 mm</td></tr><tr><td style="width:180px">Enterococcus spp.</td><td style="width:164px">&le;2 &mu;g/mL<br /><strong>&ge;</strong>17 mm</td><td style="width:186px"><strong>&ge;</strong>8 &mu;g/mL<br />&le;13 mm</td></tr><tr><td style="width:180px">H.influenzae M.catarrhalis<br /><sup>1</sup></td><td style="width:164px">&le;2 &mu;g/mL<br /><strong>&ge;</strong>17 mm</td><td style="width:186px">&nbsp;</td></tr><tr><td style="width:180px">Streptococcus pneumoniae</td><td style="width:164px">&le;2 &mu;g/mL<br /><strong>&ge;</strong>17 mm</td><td style="width:186px"><strong>&ge;</strong>8 &mu;g/mL<br />&le;13 mm</td></tr><tr><td style="width:180px">beta-hemolytic<br />Streptococcus</td><td style="width:164px">&le;2 &mu;g/mL<br /><strong>&ge;</strong>17 mm</td><td style="width:186px"><strong>&ge;</strong>8 &mu;g/mL<br />&le;13 mm</td></tr><tr><td colspan="3" style="width:179px"><sup>1</sup> The absence or rare occurrence of resistant strains precludes defining any results categories<br />other than &laquo; susceptible &raquo;. For strains yielding results suggestive of a &laquo; nonsuceptible &raquo;<br />category, organism identification and antimicrobial susceptibility test results should be<br />confirmed by a reference laboratory using CLSI reference dilution method.</td></tr></tbody></table><p><em><strong>Antibacterial spectrum</strong></em><br />The prevalence of resistance may vary geographically and with time for selected species and<br />local information on resistance is desirable, particularly when treating severe infections. As<br />necessary, expert advice should be sought when the local prevalence of resistance is such that<br />the utility of the agent in at least some types of infections is questionable</p><p><strong><u>Commonly susceptible species<br />Aerobic Gram-positive bacteria</u></strong><br /><em>Staphylococcus aureus* methicillin-susceptible<br />Staphylococcus saprophyticus<br />Streptococci, group C and G<br />Streptococcus agalactiae<br />Streptococcus pneumoniae *<br />Streptococcus pyogenes *</em><br /><u><strong>Aerobic Gram- negative bacteria</strong></u><br /><em>Burkholderia cepacia$<br />Eikenella corrodens<br />Haemophilus influenzae *<br />Haemophilus para-influenzae *<br />Klebsiella oxytoca<br />Klebsiella pneumoniae *<br />Moraxella catarrhalis *<br />Pasteurella multocida<br />Proteus vulgaris</em></p><p><em>Providencia rettgeri</em><br /><u><strong>Anaerobic bacteria</strong></u><br /><em>Peptostreptococcus</em><br /><u><strong>Other</strong></u><br /><em>Chlamydophila pneumoniae *<br />Chlamydophila psittaci<br />Chlamydia trachomatis<br />Legionella pneumophila*<br />Mycoplasma pneumoniae *<br />Mycoplasma hominis<br />Ureaplasma urealyticum</em><br /><u><strong>Species for which acquired resistance may be a problem<br />Aerobic Gram-positive bacteria</strong></u><br /><em>Enterococcus faecalis*<br />Staphylococcus aureus methicillin-resistant<br />Staphylococcus coagulase spp</em><br /><u><strong>Aerobic Gram- negative bacteria</strong></u><br /><em>Acinetobacter baumannii *<br />Citrobacter freundii *<br />Enterobacter aerogenes<br />Enterobacter agglomerans<br />Enterobacter cloacae *<br />Escherichia coli *<br />Morganella morganii *<br />Proteus mirabilis *<br />Providencia stuartii<br />Pseudomonas aeruginosa*<br />Serratia marcescens *</em><br /><u><strong>Anaerobic bacteria</strong></u><br /><em>Bacteroides fragilis<br />Bacteroides ovatus$<br />Bacteroides thetaiotamicron$<br />Bacteroides vulgatus$<br />Clostridium difficile$</em><br />* Clinical efficacy has been demonstrated for susceptible isolates in the approved clinical<br />indications.<br />$ Natural intermediate susceptibility<br /><em><strong>Other information</strong></em><br />Nosocomial infections due to P. aeruginosa may require combination therapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><strong>Absorption</strong></em><br />Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma<br />concentrations being obtained within 1h. The absolute bioavailability is approximately 100 %.<br />Food has little effect on the absorption of levofloxacin.<br /><em><strong>Distribution</strong></em><br />Approximately 30 - 40 % of levofloxacin is bound to serum protein. 500 mg once daily<br />multiple dosing with levofloxacin showed negligible accumulation. There is modest but<br />predictable accumulation of levofloxacin after doses of 500 mg twice daily. Steady state is<br />achieved within 3 days.<br /><strong><em>Penetration into tissues and body fluids:</em><br />Penetration into Bronchial Mucosa, Epithelial Lining Fluid (ELF)</strong><br />Maximum levofloxacin concentrations in bronchial mucosa and epithelial lining fluid after 500<br />mg p.o. were 8.3 &mu;g/g and 10.8 &mu;g/ml respectively. These were reached approximately one<br />hour after administration.<br /><strong>Penetration into Lung Tissue</strong><br />Maximum levofloxacin concentrations in lung tissue after 500 mg p.o. were approximately<br />11.3 &mu;g/g and were reached between 4 and 6 hours after administration. The concentrations in<br />the lungs consistently exceeded those in plasma.<br /><strong>Penetration into Blister Fluid</strong><br />Maximum levofloxacin concentrations of about 4.0 and 6.7 &mu;g/ml in the blister fluid were<br />reached 2 - 4 hours after administration following 3 days dosing at 500 mg once or twice daily,<br />respectively.<br /><strong>Penetration into Cerebro-Spinal Fluid</strong><br />Levofloxacin has poor penetration into cerebro-spinal fluid.<br /><strong>Penetration into prostatic tissue</strong><br />After administration of oral 500mg levofloxacin once a day for three days, the mean<br />concentrations in prostatic tissue were 8.7 &mu;g/g, 8.2 &mu;g/g and 2.0 &mu;g/g respectively after 2<br />hours, 6 hours and 24 hours; the mean prostate/plasma concentration ratio was 1.84.<br /><strong>Concentration in urine</strong><br />The mean urine concentrations 8 -12 hours after a single oral dose of 150 mg, 300 mg or 500<br />mg levofloxacin were 44 mg/L, 91 mg/L and 200 mg/L, respectively.<br /><strong>Biotransformation</strong><br />Levofloxacin is metabolised to a very small extent, the metabolites being desmethyllevofloxacin<br />and levofloxacin N-oxide. These metabolites account for &lt; 5 % of the dose<br />excreted in urine. Levofloxacin is stereo chemically stable and does not undergo chiral<br />inversion.<br /><strong>Elimination</strong><br />Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly<br />from the plasma (t&frac12;: 6 - 8 h). Excretion is primarily by the renal route (&gt; 85 % of the<br />administered dose).<br />There are no major differences in the pharmacokinetics of levofloxacin following intravenous<br />and oral administration, suggesting that the oral and intravenous routes are interchangeable.<br /><strong>Linearity</strong></p><p>Levofloxacin obeys linear pharmacokinetics over a range of 50 to 600 mg.<br /><strong>Subjects with renal insufficiency</strong><br />The pharmacokinetics of levofloxacin is affected by renal impairment. With decreasing renal<br />function, renal elimination and clearance are decreased, and elimination half-lives increased as<br />shown in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Cl<sub>cr</sub>&nbsp;[ml/min]</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>20 - 49</p></td><td style="vertical-align:top"><p>50 - 80</p></td></tr><tr><td style="vertical-align:top"><p>Cl<sub>R</sub>&nbsp;[ml/min]</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>57</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub>&nbsp;[h]</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>9</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Elderly subjects</strong><br />There are no significant differences in levofloxacin pharmacokinetics between young and<br />elderly subjects, except those associated with differences in creatinine clearance.<br /><strong>Gender differences</strong><br />Separate analysis for male and female subjects showed small to marginal gender differences in<br />levofloxacin pharmacokinetics. There is no evidence that these gender differences are of<br />clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Acute toxicity</strong><br />The median lethal dose (LD50) values obtained in mice and rats after oral administration of<br />levofloxacin were in the range 1500-2000 mg/kg.<br />Administration of 500 mg/kg p.o. to monkeys induced little effect apart from vomiting.<br /><strong>Repeated dose toxicity</strong><br />Studies of one and six month&#39;s duration by gavages have been carried out in the rat and<br />monkey. Doses were 50, 200, 800 mg/kg/day and 20, 80, 320 mg/kg/day for 1 and 6 months in<br />the rat and 10, 30, 100 mg/kg/day and 10, 25, 62.5 mg/kg/day for 1 and 6 months in the<br />monkey.<br />Signs of reaction to treatment were minor in the rat with slight effects principally at 200<br />mg/kg/day and above in reducing food consumption and slightly altering haematological and<br />biochemical parameters. The No Observed Adverse Effect Levels (NOELs) in these studies<br />were concluded to be 200 and 20 mg/kg/day after 1 and 6 months respectively.<br />Toxicity after oral dosing in the monkey was minimal with reduced body weight at 100<br />mg/kg/day together with salivation, diarrhoea and decreased urinary pH in some animals at this<br />dose. No toxicity was seen in the 6-month study. The NOELs were concluded to be 30 and<br />62.5 mg/kg/day after 1 and 6 months respectively.</p><p>The NOELs in the six-month studies were concluded to be 20 and 62.5 mg/kg/day in the rat<br />and monkey respectively.<br /><strong>Reproductive toxicity</strong><br />Levofloxacin caused no impairment of fertility or reproductive performance in rats at oral<br />doses as high as 360 mg/kg/day or intravenous doses up to 100 mg/kg/day.<br />Levofloxacin was not teratogenic in rats at oral doses as high as 810 mg/kg /day or at<br />intravenous doses as high as 160 mg/kg/day. No teratogenicity was observed when rabbits<br />were dosed orally with up to 50 mg/kg/day or intravenously with up to 25 mg/kg/day.<br />Levofloxacin had no effect on fertility and its only effect on foetuses was delayed maturation<br />as a result of maternal toxicity.<br /><strong>Genotoxicity</strong><br />Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce<br />chromosome aberrations in Chinese hamster lung cells in vitro at or above 100 &mu;g/ml, in the<br />absence of metabolic activation. In vivo tests (micronucleus, sister chromatid exchange,<br />unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.<br /><strong>Phototoxic potential</strong><br />Studies in the mouse after both oral and intravenous dosing showed levofloxacin to have<br />phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential<br />in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenicity<br />assay.<br /><strong>Carcinogenic potential</strong><br />No indication of carcinogenic potential was seen in a two year study in the rat with dietary<br />administration (0, 10, 30 and 100 mg/kg/day).<br /><strong>Toxicity to joints</strong><br />In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering<br />and cavities) in rats and dogs. These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Active Ingredient:</strong><br />Levofloxacin Hemihydrate (equivalent to Levofloxacin&hellip;250 mg).<br /><strong>Excipients for Core:</strong><br />Hydroxypropyl Methylcellulose EP.<br />Crospovidone NF.<br />Silicified Microcrystalline Cellulose (Prosolv <strong>SMCC</strong> 50).<br />Magnesium Stearate.<br /><strong>Excipients for Film Coating:</strong><br />Polysorbate 80 EP.<br />Titanium Dioxide EP.<br />Purified Talc EP.<br />Polyethylene Glycol MW 6000 EP.<br />Hydroxypropyl Methylcellulose EP.<br />Iron Oxide Yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister Pack.<br />Lidding material: Aluminum Foil<br />Forming Film: PVC/PVDC.<br />(PVC: polyvinyl chloride, PVDC polyvinylidene chloride)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2016.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>